Wedbush Has Negative Forecast for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities research analysts at Wedbush lowered their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research report issued to clients and investors on Wednesday, February 26th. Wedbush analyst Y. Zhong now anticipates that the company will post earnings of ($0.76) per share for the quarter, down from their prior forecast of ($0.51). Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics’ Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.31) EPS, FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($0.19) EPS and FY2029 earnings at $3.85 EPS.

A number of other research analysts also recently issued reports on the company. The Goldman Sachs Group cut their price objective on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Thursday. Finally, Needham & Company LLC increased their price target on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of “Buy” and an average target price of $83.20.

MoonLake Immunotherapeutics Stock Performance

NASDAQ MLTX opened at $41.77 on Friday. The business’s fifty day moving average is $46.90 and its 200 day moving average is $48.99. The company has a market capitalization of $2.67 billion, a PE ratio of -32.38 and a beta of 1.28. MoonLake Immunotherapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.09).

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently made changes to their positions in MLTX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of MoonLake Immunotherapeutics by 96.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,814 shares of the company’s stock valued at $1,806,000 after buying an additional 17,580 shares during the period. Erste Asset Management GmbH purchased a new position in MoonLake Immunotherapeutics during the 3rd quarter valued at $741,000. Barclays PLC boosted its holdings in MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after acquiring an additional 5,229 shares during the period. State Street Corp increased its stake in MoonLake Immunotherapeutics by 96.2% in the third quarter. State Street Corp now owns 87,637 shares of the company’s stock worth $4,419,000 after purchasing an additional 42,980 shares during the period. Finally, Congress Asset Management Co. lifted its position in shares of MoonLake Immunotherapeutics by 9.5% during the fourth quarter. Congress Asset Management Co. now owns 72,993 shares of the company’s stock worth $3,953,000 after purchasing an additional 6,352 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.